Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum: Targeting thymidylate synthase enhances the chemosensitivity of triple-negative breast cancer towards 5-FU-based combinatorial therapy.
Haritha NH, Nawab A, Vijayakurup V, Anto NP, Liju VB, Alex VV, Amrutha AN, Aiswarya SU, Swetha M, Vinod BS, Sundaram S, Guijarro MV, Herlevich T, Krishna A, Nestory NK, Bava SV, Sadasivan C, Zajac-Kaye M, Anto RJ. Haritha NH, et al. Among authors: zajac kaye m. Front Oncol. 2023 Dec 15;13:1302413. doi: 10.3389/fonc.2023.1302413. eCollection 2023. Front Oncol. 2023. PMID: 38162481 Free PMC article.
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival.
Guijarro MV, Kellish PC, Dib PE, Paciaroni NG, Nawab A, Andring J, Kulemina L, Borrero NV, Modenutti C, Feely M, Nasri E, Seifert RP, Luo X, Bennett RL, Shabashvili D, Licht JD, McKenna R, Roitberg A, Huigens RW 3rd, Kaye FJ, Zajac-Kaye M. Guijarro MV, et al. Among authors: zajac kaye m. JCI Insight. 2023 Apr 25;8(10):e158798. doi: 10.1172/jci.insight.158798. JCI Insight. 2023. PMID: 37097751 Free PMC article.
PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.
Khan S, Cao L, Wiegand J, Zhang P, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. Khan S, et al. Among authors: zajac kaye m. bioRxiv [Preprint]. 2024 Mar 1:2024.02.27.582353. doi: 10.1101/2024.02.27.582353. bioRxiv. 2024. Update in: Cells. 2024 Mar 17;13(6):528. doi: 10.3390/cells13060528 PMID: 38464204 Free PMC article. Updated. Preprint.
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice.
Khan S, Kellish P, Connis N, Thummuri D, Wiegand J, Zhang P, Zhang X, Budamagunta V, Hua N, Yang Y, De U, Jin L, Zhang W, Zheng G, Hromas R, Hann C, Zajac-Kaye M, Kaye FJ, Zhou D. Khan S, et al. Among authors: zajac kaye m. Cell Death Discov. 2023 Jan 2;9(1):1. doi: 10.1038/s41420-022-01296-8. Cell Death Discov. 2023. PMID: 36588105 Free PMC article.
Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial Therapy.
Haritha NH, Nawab A, Vijayakurup V, Anto NP, Liju VB, Alex VV, Amrutha AN, Aiswarya SU, Swetha M, Vinod BS, Sundaram S, Guijarro MV, Herlevich T, Krishna A, Nestory NK, Bava SV, Sadasivan C, Zajac-Kaye M, Anto RJ. Haritha NH, et al. Among authors: zajac kaye m. Front Oncol. 2021 Jul 15;11:656804. doi: 10.3389/fonc.2021.656804. eCollection 2021. Front Oncol. 2021. PMID: 34336653 Free PMC article.
MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.
Jiang Y, Gao R, Cao C, Forbes L, Li J, Freeberg S, Fredenburg KM, Justice JM, Silver NL, Wu L, Varma S, West R, Licht JD, Zajac-Kaye M, Kentsis A, Kaye FJ. Jiang Y, et al. Among authors: zajac kaye m. Oral Oncol. 2019 Nov;98:147-155. doi: 10.1016/j.oraloncology.2019.09.005. Epub 2019 Oct 10. Oral Oncol. 2019. PMID: 31606723 Free PMC article.
63 results